Journal of Equine Veterinary Science 34 (2014) 1051–1054

Contents lists available at ScienceDirect

Journal of Equine Veterinary Science

journal homepage: www.j-evs.com



Original Research

Seroprevalence of *Sarcocystis neurona* and Its Association With Neurologic Disorders in Argentinean Horses

Gastón Moré PhD [a,b,*], Aldana Vissani PhD [c], Lais Pardini PhD [a,b], Marta Monina PhD [d], Marcos Muriel MD [e], Daniel Howe PhD [f], Maria Barrandeguy PhD [c], Maria C. Venturini PhD [a]

[a] *Laboratorio de Inmunoparasitología, FCV-UNLP, La Plata, Buenos Aires, Argentina*
[b] *Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina*
[c] *Laboratorio de Virus Equinos Instituto de Virología, INTA Las Cabañas y Los Reseros S/N, Buenos Aires, Argentina*
[d] *Cátedra de Semiología y Propedéutica, FCV-UNLPam, La Pampa, Argentina*
[e] *Hospital escuela, FCV-UNLP, La Plata, Buenos Aires, Argentina*
[f] *Department of Veterinary Science, University of Kentucky, 108 Gluck Equine Research Center, Lexington, KY*

A R T I C L E I N F O

Article history:
Received 18 December 2013
Received in revised form 16 May 2014
Accepted 5 June 2014
Available online 12 June 2014

Keywords:
Sarcocystis neurona
EPM
Immunoblot
Horse
Argentina

A B S T R A C T

Equine protozoal myeloencephalitis (EPM) is generally caused by *Sarcocystis neurona* and can produce substantial economic losses on equine production in America. The aims of the present study were to evaluate the seroprevalence of *S. neurona* in the main horse-production area of Argentina and associate it with the occurrence of neurologic disorders. Serum samples were collected from 640 horses in nine Argentinean provinces. Most of the samples correspond to animals ≥1.5-year-old from different breeds (n = 628); 12 samples were from younger horses. Further seroprevalence comparison was conducted from the older animals grouped with (n = 148) or without neurologic signs (n = 480). Immunoblot: proteins from 2×10^7 *S. neurona* merozoites were used as antigen on each membrane. Reactivity to antigens with relative mobility of 7, 10, and 16 kDa was considered specific for antibodies against *S. neurona*; reactivity at 30 kDa was recorded separately. The overall seroprevalence for *S. neurona* was 26.1% (167/640), and all the provinces had positive horses. Seroprevalence of animals with neurologic signs was greater ($P < .001$) than what was observed in normal horses (39.2% vs. 22.1%), with an odds ratio of 2.27. Reactivity at 30 kDa was detected in 71% of all samples. This study identified a wide distribution of *S. neurona*–positive animals in Argentina and horses with neurologic signs having a greater seroprevalence than normal horses. *Sarcocystis neurona* infection should be considered for early differential diagnosis and treatment of animals with neurologic disorders to decrease the economic impact of EPM in Argentina.

© 2014 Elsevier Inc. All rights reserved.

1. Introduction

Equine protozoal myeloencephalitis (EPM) is generally caused by *Sarcocystis neurona* and could produce substantial economical losses on equine production in the Western Hemisphere [1]. Geographical distribution of this apicomplexan parasite is related to the distribution of their definitive hosts, the opossums *Didelphis albiventris* and *Didelphis virginiana* [2,3]. The South American opossum (*D. albiventris*) is frequently observed in farms and suburban areas of Argentina. However, all the attempts to isolate *S. neurona* from Argentinean opossums have thus far resulted in identification of other *Sarcocystis* species [4,5].

The principal signs of EPM are diverse neurologic disorders, mainly ataxia and focal muscle atrophy, which

* Corresponding author at: Gastón Moré, PhD, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, Calle 60 y 118, (1900) La Plata, Argentina.
E-mail address: gastonmore@fcv.unlp.edu.ar (G. Moré).

0737-0806/$ – see front matter © 2014 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.jevs.2014.06.002

occur generally in adult horses [1]. Subclinical infections are common, similar to what occurs with other *Sarcocystis* spp. infections [1,6,7]. Serologic tests such as immunofluorescence antibody test, immunoblot, and Enzyme-Linked ImmunoSorbent Assay with recombinant proteins are the most important tools for demonstrating *S. neurona* infection [1,8–10]. However, the simple detection of antibodies against *S. neurona* is only indicative of parasite exposure and not always related to the development of clinical signs [1,11]. Traditionally, most of the serologic studies have been performed in the United States with the immunoblot and Enzyme-Linked ImmunoSorbent Assay as reference tests [1,12–14]. Regarding interpretation of immunoblot results, the *S. neurona* antigens that migrate at around 30 kDa are considered immunodominant, but their diagnostic value is uncertain [1,14–16].

In Argentina, information regarding *S. neurona* infection has been restricted to a study demonstrating seropositivity in 27 of 76 horses (35.5%) without neurologic signs from Chaco, a Northern Province [17]. The distribution of *S. neurona* infections and its relation with the detection of clinical signs in Argentinean horses remain unknown. Other serologic studies performed in the United States, Mexico, Costa Rica, and Brazil using large number of samples ($n \geq 315$) demonstrated seroprevalences ranging from 33.6% to 89.2%, with greater values for older animals [1,13–15,18–20].

The aims of the present study were to evaluate the seroprevalence of *S. neurona* in the main horse-production area of Argentina and associate the *S. neurona* serologic status with the occurrence of neurologic signs.

2. Material and Methods

2.1. Samples

A total of 640 horses' serum samples from nine Argentinean Provinces were collected and preserved at $-20°$C until serologic analysis was performed. Most of the samples correspond to animals $\geq$1.5-year-old (adults) from different breeds ($n = 628$), with 12 samples from younger horses exhibiting neurologic signs (ranging between 2-days-old and 14-months-old). To compare seroprevalences for *S. neurona* and associate this with the occurrence of neurologic disorders, the animals $\geq$1.5-year-old were divided into two groups: (1) horses with neurologic clinical signs ($n = 148$) collected from 2006 until 2011 and (2) horses without neurologic signs ($n = 480$) collected during 2010. Samples from animals with neurologic signs were collected during clinical evaluation performed by some of the authors. A few of these horses were sampled more than once, but the consecutive samples and serologic follow-ups were not included in the present study. Samples from animals showing no clinical signs were collected in the field by veterinary practitioners participating in a viral diseases surveillance program. Most horses were sampled in Buenos Aires Province ($n = 531$) followed by Cordoba ($n = 51$), Santa Fe ($n = 11$), La Pampa ($n = 8$), Corrientes ($n = 5$), Santiago del Estero ($n = 4$), San Juan ($n = 4$), Neuquen ($n = 1$), Entre Rios ($n = 1$), and origin not declared ($n = 24$). The sampled area represents the main horse-production region of Argentina.

2.2. Immunoblot

Proteins from 2×10^7 cell culture–derived merozoites of *S. neurona* SN3 strain were separated in 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels in the presence of 2-mercaptoethanol. A low-range molecular marker was used (Bio-Rad). Proteins were transferred to a polyvinylidene difluoride membrane, which was cut into around 40 strips. Blocking solution was 5% nonfat dried milk in phosphate-buffered saline (PBS)–Tween 20 (0.2%); serum samples were diluted 1/10 and control reference sera 1/300 in blocking solution. Antihorse immunoglobulin G peroxidase conjugate (1/500 in blocking solution) was used as the secondary antibody. Blocking and serum and conjugate incubation steps were performed at room temperature for 1 hour each in a rotational shaker. After the incubations, three washings of 3 minutes each were performed with PBS–Tween 20 (0.05%) solution. The last washing step was performed with PBS. Reactions were revealed with chloronafthol–H_2O_2 in PBS–ethanol solution. Reactivity to antigens with relative mobility of 7–10 and 16 kDa was considered specific for antibodies against *S. neurona* [1,14]; reactivity at 30 kDa was recorded separately.

2.3. Statistical Analysis

The differences in *S. neurona* seroprevalence between symptomatic and asymptomatic horses were analyzed with chi square for proportions and calculating the odds ratio using the Win Episcope 2.0 software. The difference between seropositivity in Buenos Aires province versus the other sampled regions was analyzed by chi square for proportions (significant values $P < .05$).

3. Results

The overall seroprevalence for *S. neurona* was 26.1% (167/640), and all Provinces with more than four samples showed at least two positive horses. Samples from animals $\geq$1.5-years-old showed a seropositivity of 26.15% (164/628), whereas 25% (3/12) of young horses tested positive (one of 1-month-old and two of 6-months-old). There was no significant difference in the proportion of seropositive animals from Buenos Aires province versus other regions ($P \geq .05$).

Comparison of animals $\geq$1.5-years-old revealed that the group with neurologic signs had a seroprevalence of 39.2% (58/148), significantly greater ($P < .001$) than the 22.1% (106/480) observed in the normal horse group. Parasite exposure in all horses based on positive serology to *S. neurona* and the occurrence of clinical signs had an odds ratio value of 2.27 (95% confidence interval, 1.53–3.37).

Reactivity to 30 kDa protein band was detected in 71% of all samples (455/640), with 79% (117/148) and 69% (332/480) testing positive in horses with or without neurologic disorders, respectively. Reactivity at 30 kDa was observed in 50% (6/12) of the young animals. Of the samples considered positives to *S. neurona*, 98% (164/167) reacted at 30 kDa.

4. Discussion

The present study identified a wide distribution of *S. neurona*–positive horses in the main horse-production area of Argentina. Most samples belong to adult animals and were collected in Buenos Aires Province, but no significant differences were found when the seropositivity was compared with the remaining sampled provinces. The overall seroprevalence detected in the present study was lower than what has been previously reported from the United States [1], Mexico [19], Costa Rica [18], and Brazil [13] but similar to the previous study carried out in Chaco Province, Argentina [17], and the seroprevalence in Northern Colorado, United States [20]. The differences could be explained by a lower parasite distribution and consequently decreased horse exposure in Argentina but also by the immunologic characteristics of serologic assays and interpretation of results in these studies. Cross reactivity between *Sarcocystis* spp. in serologic test can occur, thus yielding false-positive results [1,7]. In the present study, we recorded an overall seroreactivity of 71% against the 30 kDa band, which is considered immunodominant for *S. neurona* infections [1,16]. This suggested that immunodominancy is supported by the fact that almost all *S. neurona*–seropositive horses from Argentina reacted against the 30 kDa antigens. However, the specificity of antibodies recognizing the 30 kDa antigens has been questioned [1], and some researchers have proposed that treatment of the immunoblot with a heterologous serum sample (bovine *Sarcocystis cruzi*-positive serum) improves specificity [16]. In the present study, no "heterologous treatment" was applied, and we presumed that the high reactivity to the *S. neurona* 30 kDa antigens could be because of antibodies against other *Sarcocystis* spp. such as *Sarcocystis fayeri* or *Sarcocystis equicanis* that normally cause subclinical infections and are reported with high prevalence in other countries and probably worldwide [1,6,7]. Importantly, the 30 kDa band in the *S. neurona* immunoblot comprises both the *Sarcocystis neurona* surface antigens (SnSAG) SnSAG1 and SnSAG4 parasite surface antigens [21], and it is conceivable that additional immunoreactive molecules also migrate to this region of the gel. Of the two SnSAGs that migrate at 30 kDa, SnSAG1 appears to be much more abundant, so it is notable that prior work has demonstrated that SnSAG1 is not expressed in all strains of *S. neurona* [22]. This likely explains the three horse serum samples that showed a specific immunoblot profile for *S. neurona* but did not react at 30 kDa.

Interestingly, animals with neurologic signs showed a greater seroprevalence than normal horses, suggesting that some of these horses could have been suffering from EPM caused by *S. neurona*. Moreover, the odds ratio value obtained suggested more than double the risk of neurologic signs for the *S. neurona*–seropositive animals. Based on these findings, it is reasonable to assume that *S. neurona* is widely distributed and probably causing EPM in Argentinean horses. However, studies performed in the United States revealed that only a small percentage of horses exposed to *S. neurona* develop EPM.

It is important to mention that 60.8% (90/148) of the horses with neurologic signs showed no serologic evidence of *S. neurona* infection. Therefore, a complete differential diagnosis should be carried out to exclude other causes of neurologic disorders.

The identification of antibodies to *S. neurona* (25%), as well as to the 30 kDa antigens (50%), in horses <6 months could be because of detection of residual maternal antibodies [1,23]. However, because these young horses showed neurologic signs, the involvement of *S. neurona* as causative agent could not be completely excluded. Infections with other *Sarcocystis* species have been detected in calves, probably due to early exposure to sporocysts under grazing conditions in Argentina [24], and the same could be true for young horses. Further studies are needed to clarify the epidemiology of EPM in young horses.

The wide distribution of horses exhibiting antibodies against *S. neurona* and the positive association with the occurrence of neurologic clinical signs indicate that this protozoan parasite should be considered in the early differential diagnosis and treatment of animals with neurologic disorders to decrease the economic impact of EPM in Argentina.

Acknowledgments

The authors thank Isidoro Ercoli for his excellent technical assistance. The study was financially supported through the research projects from La Plata University Codes V179 and V213 and a CONICET postdoctoral fellowship (G.M.).

References

[1] Dubey JP, Lindsay DS, Saville WJ, Reed SM, Granstrom DE, Speer CA. A review of *Sarcocystis neurona* and equine protozoal myeloencephalitis (EPM). Vet Parasitol 2001;95(2-4):89–131.

[2] Dubey JP, Lindsay DS, Kerber CE, Kasai N, Pena HF, Gennari SM, et al. First isolation of *Sarcocystis neurona* from the South American opossum, *Didelphis albiventris*, from Brazil. Vet Parasitol 2001; 95(2-4):295–304.

[3] Fenger CK, Granstrom DE, Langemeier JL, Stamper S, Donahue JM, Patterson JS, et al. Identification of opossums (*Didelphis virginiana*) as the putative definitive host of *Sarcocystis neurona*. J Parasitol 1995;81(6):916–9.

[4] Dubey JP, Speer CA, Bowman DD, Horton KM, Venturini C, Venturini L. Experimental transmission of *Sarcocystis speeri* Dubey and Lindsay, 1999 from the South American opossum (*Didelphis albiventris*) to the North American opossum (*Didelphis virginiana*). J Parasitol 2000;86(3):624–7.

[5] Dubey JP, Venturini L, Venturini C, Basso W, Unzaga J. Isolation of *Sarcocystis falcatula* from the South American opossum (*Didelphis albiventris*) from Argentina. Vet Parasitol 1999;86(4):239–44.

[6] Fukuyo M, Battsetseg G, Byambaa B. Prevalence of *Sarcocystis* infection in horses in Mongolia. Southeast Asian J Trop Med Public Health 2002;33(4):718–9.

[7] Dubey JP, Speer CA, Fayer R. Sarcocystosis of animals and man. First ed. Boca Raton, USA: CRC press; 1989.

[8] Hoane JS, Morrow JK, Saville WJ, Dubey JP, Granstrom DE, Howe DK. Enzyme-linked immunosorbent assays for detection of equine antibodies specific to *Sarcocystis neurona* surface antigens. Clin Diagn Lab Immunol 2005;12(9):1050–6.

[9] Duarte PC, Daft BM, Conrad PA, Packham AE, Gardner IA. Comparison of a serum indirect fluorescent antibody test with two Western blot tests for the diagnosis of equine protozoal myeloencephalitis. J Vet Diagn Invest 2003;15(1):8–13.

[10] Granstrom DE, Dubey JP, Davis SW, Fayer R, Fox JC, Poonacha KB, et al. Equine protozoal myeloencephalitis: antigen analysis of cultured *Sarcocystis neurona* merozoites. J Vet Diagn Invest 1993;5(1):88–90.

[11] Tornquist SJ, Boeder LJ, Mattson DE, Cebra CK, Bildfell RJ, Hamir AN. Lymphocyte responses and immunophenotypes in horses with *Sarcocystis neurona* infection. Equine Vet J 2001;33(7):726–9.

[12] Yeargan MR, Howe DK. Improved detection of equine antibodies against *Sarcocystis neurona* using polyvalent ELISAs based on the parasite SnSAG surface antigens. Vet Parasitol 2011;176(1):16–22.
[13] Hoane JS, Gennari SM, Dubey JP, Ribeiro MG, Borges AS, Yai LE, et al. Prevalence of *Sarcocystis neurona* and *Neospora* spp. infection in horses from Brazil based on presence of serum antibodies to parasite surface antigen. Vet Parasitol 2006;136(2):155–9.
[14] Bentz BG, Ealey KA, Morrow J, Claypool PL, Saliki JT. Seroprevalence of antibodies to *Sarcocystis neurona* in equids residing in Oklahoma. J Vet Diagn Invest 2003;15(6):597–600.
[15] Rossano MG, Kaneene JB, Marteniuk JV, Banks BD, Schott HC, Mansfield LS. The seroprevalence of antibodies to *Sarcocystis neurona* in Michigan equids. Prev Vet Med 2001;48(2):113–28.
[16] Rossano MG, Mansfield LS, Kaneene JB, Murphy AJ, Brown CM, Schott HC, et al. Improvement of western blot test specificity for detecting equine serum antibodies to *Sarcocystis neurona*. J Vet Diagn Invest 2000;12(1):28–32.
[17] Dubey JP, Venturini MC, Venturini L, McKinney J, Pecoraro M. Prevalence of antibodies to *Sarcocystis neurona, Toxoplasma gondii* and *Neospora caninum* in horses from Argentina. Vet Parasitol 1999;86(1):59–62.
[18] Dangoudoubiyam S, Oliveira J, Viquez C, Gomez-Garcia A, Gonzalez O, Romero J, et al. Detection of antibodies against *Sarcocystis neurona, Neospora* spp., and *Toxoplasma gondii* in horses from Costa Rica. J Parasitol 2011;97(3):522–4.
[19] Yeargan MR, Alvarado-Esquivel C, Dubey JP, Howe DK. Prevalence of antibodies to *Sarcocystis neurona* and *Neospora hughesi* in horses from Mexico. Parasite 2013;20:29.
[20] Tillotson K, McCue PM, Granstrom DE, Darga DA, Smith MO, Traub-Dargatz JL. Seroprevalence of antibodies to *Sarcocystis neurona* in horses residing in Northern Colorado. J Equine Vet Sci 1999;19(2):122–6.
[21] Howe DK, Gaji RY, Marsh AE, Patil BA, Saville WJ, Lindsay DS, et al. Strains of *Sarcocystis neurona* exhibit differences in their surface antigens, including the absence of the major surface antigen SnSAG1. Int J Parasitol 2008;38(6):623–31.
[22] Howe DK, Gaji RY, Mroz-Barrett M, Gubbels MJ, Striepen B, Stamper S. *Sarcocystis neurona* merozoites express a family of immunogenic surface antigens that are orthologues of the *Toxoplasma gondii* surface antigens (SAGs) and SAG-related sequences. Infect Immun 2005;73(2):1023–33.
[23] Cook AG, Buechner-Maxwell V, Morrow JK, Ward DL, Parker NA, Dascanio JJ, et al. Interpretation of the detection of *Sarcocystis neurona* antibodies in the serum of young horses. Vet Parasitol 2001;95(2-4):187–95.
[24] Moré G, Bacigalupe D, Basso W, Rambeaud M, Venturini MC, Venturini L. Serologic profiles for *Sarcocystis* sp. and *Neospora caninum* and productive performance in naturally infected beef calves. Parasitol Res 2010;106(3):689–93.